Abstract:Importance: Animal and human studies have suggested that the use of angiotensin receptor blockers (ARBs) may be associated with a lower risk of incident epilepsy compared with other antihypertensive medications. However, observational data from the US are lacking. Objective: To evaluate the association between ARB use and epilepsy incidence in subgroups of US patients with hypertension. Design, setting, and participants: This retrospective cohort study used data from a national health administrative database from January 2010 to December 2017 with propensity score (PS) matching. The eligible cohort included privately insured individuals aged 18 years or older with diagnosis of primary hypertension and dispensed at least 1 ARB, angiotensin-converting enzyme inhibitor (ACEI), β-blocker, or calcium channel blocker (CCB) from 2010 to 2017. Patients with a diagnosis of epilepsy at or before the index date or dispensed an antiseizure medication 12 months before or 90 days after initiating the study medications were excluded. The data analysis for this project was conducted from April 2022 to April 2024. Exposures: Propensity scores were generated based on baseline covariates and used to match patients who received ARBs with those who received either ACEIs, β-blockers, CCBs, or a combination of these antihypertensive medications. Main outcomes and measures: Cox regression analyses were used to evaluate epilepsy incidence during follow-up comparing the ARB cohort with other antihypertensive classes. Subgroup and sensitivity analyses were conducted to examine the association between ARB use and epilepsy incidence in various subgroups. Results: Of 2 261 964 patients (mean [SD] age, 61.7 [13.9] years; 1 120 630 [49.5%] female) included, 309 978 received ARBs, 807 510 received ACEIs, 695 887 received β-blockers, and 448 589 received CCBs. Demographic and clinical characteristics differed across the 4 comparison groups prior to PS matching. Compared with ARB users, patients receiving ACEIs were predominantly male and had diabetes, CCB users were generally older (eg, >65 years), and β-blocker users had more comorbidities and concurrent medications. The 1:1 PS-matched subgroups included 619 858 patients for ARB vs ACEI, 619 828 patients for ARB vs β-blocker, and 601 002 patients for ARB vs CCB. Baseline characteristics were equally distributed between comparison groups after matching with propensity scores. Use of ARBs was associated with a decreased incidence of epilepsy compared with ACEIs (adjusted hazard ratio [aHR], 0.75; 95% CI, 0.58-0.96), β-blockers (aHR, 0.70; 95% CI, 0.54-0.90), and a combination of other antihypertensive classes (aHR, 0.72; 95% CI, 0.56-0.95). Subgroup analyses revealed a significant association between ARB use (primarily losartan) and epilepsy incidence in patients with no preexisting history of stroke or cardiovascular disease. Conclusions and relevance: This cohort study found that ARBs, mainly losartan, were associated with a lower incidence of epilepsy compared with other antihypertensive agents in hypertensive patients with no preexisting stroke or cardiovascular disease. Further studies, such as randomized clinical trials, are warranted to confirm the comparative antiepileptogenic properties of antihypertensive medications.

Association between risk of Alzheimer's disease and related dementias and angiotensin receptor Ⅱ blockers treatment for individuals with hypertension in high-volume claims data

Association between risk of Alzheimer's disease and related dementias and angiotensin receptor II blockers treatment for individuals with hypertension in high-volume claims data

Angiotensin Receptor Blockers Are Associated With a Lower Risk of Progression From Mild Cognitive Impairment to Dementia

Antihypertensive medications and dementia in older adults with hypertension

Angiotensin II Receptor Blockers in the Management of Hypertension in Preventing Cognitive Impairment and Dementia—A Systematic Review

Antihypertensive medication classes and risk of incident dementia in primary care patients: a longitudinal cohort study in the Netherlands

Associations between brain amyloid accumulation and the use of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers

Impact of Renin-Angiotensin System-Targeting Antihypertensive Drugs on Treatment of Alzheimer's Disease: a Meta-Analysis

Genetically Determined Blood Pressure, Antihypertensive Medications, and Risk of Alzheimer’s Disease: A Mendelian Randomization Study

Prevention of Dementia by Antihypertensive Drugs: How AT1-receptor-blockers and Dihydropyridines Better Prevent Dementia in Hypertensive Patients Than Thiazides and ACE-inhibitors

LESS CONVERSION TO AD AND FEWER NEUROFIBRILLARY TANGLES IN MCI PATIENTS TAKING CERTAIN ANTIHYPERTENSIVES

Anti-Hypertensive Drugs Moderate the Relationship of Blood Pressure with Alzheimer’s Pathologies and Neurodegenerative Markers in Non-Demented Hypertensive Older Adults

Association Of Acei/Arb Use And Clinical Outcomes Of Covid-19 Patients With Hypertension

Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis.

Angiotensin Receptor Blockers for Hypertension and Risk of Epilepsy

Blood Pressure, Antihypertensive Use, and Late-Life Alzheimer and Non-Alzheimer Dementia Risk: An Individual Participant Data Meta-Analysis

Prevention of Stroke and Myocardial Infarction by Amlodipine and Angiotensin Receptor Blockers: a Quantitative Overview.

Abstract TMP98: Pre-Stroke Use of Blood-Brain Barrier Crossing Angiotensin Receptor Blockers in Elderly Patients Mitigates Neurological Severity at the Onset of Acute Stroke

Risk of dementia in primary aldosteronism compared with essential hypertension: a nationwide cohort study

Certain Antihypertensives May Slow the Conversion from Mild Cognitive Impairment to Alzheimer’s Disease

Renin-angiotensin System Blockers Affect Cognitive Decline in Parkinson's Disease: the PPMI Dataset